Sources: Isomorphic Labs, an AI-powered drug discovery company spun out of Google DeepMind, is in advanced talks to raise $2B+ led by Thrive Capital
Isomorphic Labs, an AI-powered drug discovery company spun out of Alphabet Inc.'s Google DeepMind, is in advanced discussions to raise …
Context & Ripple Effects
Isomorphic Labs was created by Alphabet’s DeepMind and initially positioned around AI drug discovery. Its commercial path was already taking shape through partnerships with Eli Lilly and Novartis, alongside a $600 million Thrive-led round in March 2025.
This report marks a sharp step-up in that financing arc: subsequent related coverage says the round closed at $2.1 billion, again led by Thrive. The scale matters because it links DeepMind-derived AI research to a more heavily capitalized, independent drug-development effort.
First-order effects
- Isomorphic Labs gains the prospect—and, according to later coverage, the reality—of substantially more capital to pursue its drug-discovery programs beyond its prior $600 million round.
- Thrive strengthens its role as Isomorphic’s principal outside financial backer, while Alphabet/Google DeepMind remains associated with a better-funded spinout built on DeepMind-originated capabilities.
Second-order effects
- Existing pharmaceutical partners, including Eli Lilly and Novartis, gain a better-capitalized AI-discovery counterparty, potentially making those collaborations more consequential to Isomorphic’s development strategy.
- The financing raises the competitive bar for other AI drug-discovery companies: attracting partners is no longer the only test; companies will also need enough capital to support longer, more demanding research and development cycles.
Third-order effects
- If large follow-on rounds continue, AI drug discovery may consolidate around a smaller set of well-financed platform companies that combine frontier-model pedigrees, pharma partnerships, and patient capital.
- The case also tests whether AI labs can turn research spinouts into durable life-sciences businesses; sustained funding alone will not establish that model without demonstrable progress through drug development.
The trend: AI is moving from broadly framed research capability toward capital-intensive, partnership-led commercialization in regulated scientific industries.